Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. acmcr. 2022;6(5):660-668. Accessed September 11, 2026. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670